Skip to content
DataLookout
Menu

NCT05353439

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

StatusTerminated
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 139 versions: 3 with changes below, 47 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Withdrawal of tazemetostat supply led to early study closure. Show 5 more changesShow less
    • Primary endpoint(s) modified
    • Results posted: Nov 10, 2026
    • Enrollment increased: 18 → 22 participants
    • Study completion date changed from estimate of Mar 13, 2027 to Apr 21, 2026
    • Site details revised at 5 of 15 sites
  2. Minor Enrollment target: estimated 60 to confirmed 18
    • Primary completion date changed from estimate of Apr 1, 2027 to Feb 11, 2026
    • Study completion date: Apr 1, 2027 to Mar 13, 2027
    v119
  3. Minor Trial status: Recruiting to Active, Not Recruitingv117
  • Stopped: terminated, suspended or withdrawn
  • Minor: routine updates

Endpoints

Primary

Maximum Tolerated Dose (Dose-escalation Cohort) of Tazemetostat in Combination With Topotecan and Pembrolizumab
Timeframe: Up to 21 days (cycle 1)
Incidence of Adverse Events (Expansion Cohort) by Type and Grade in the Expansion Cohort
Timeframe: Up to 3 years
Incidence of Grade 3 or Above Adverse Events by Type Related or Possibly Related to Study Treatment in the Dose Escalation Cohort
Timeframe: Start of treatment through 30 days post last dose, an average of 112.33 days or 3.22 months

Secondary (5)

Overall Response Rate (ORR) (Expansion Cohort)
Progression-free Survival (PFS) (Expansion Cohort)
Overall Survival (OS) (Expansion Cohort)
Duration of Response (DOR) (Expansion Cohort)
Gene Expression Estimated by the Ribonucleic Acid (RNA) Sequencing in Participants With Recurrent Extensive Stage Small Cell Lung Cancer (ES-SCLC) (Dose Expansion)

Arms and interventions

Treatment (tazemetostat, pembrolizumab, topotecan)Experimental

Patients receive tazemetostat PO BID for 7 days prior to cycle 1 and then on days 1-21 of each cycle, pembrolizumab IV over 30 minutes on day 1 of each cycle, and topotecan IV over 30 minutes on days 1-3 or days 1-5 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study and undergo biopsy and collection of blood on study.

Procedures: Biopsy Procedure, Biospecimen Collection, Computed Tomography

Biologicals: Pembrolizumab

Drugs: Tazemetostat Hydrobromide, Topotecan Hydrochloride

Sites

15 sites in 1 country